Physician profile
Matthew B Smith
NPI 1508973926
$1,763.25
in general payments reported to CMS, 2019-2025
20 companies · $528 in 2025
The $528 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $127 · 2021: $12.00 · 2022: $98.81 · 2023: $642 · 2024: $356 · 2025: $528.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,526.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,525.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $748.24 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Boston Scientific Corporation | $154.75 | 2023 | Resolution Clip |
| Aimmune Therapeutics, INC. | $124.99 | 2024 | |
| Genzyme Corporation | $123.50 | 2023-2024 | |
| Medtronic, INC. | $111.92 | 2025 | Interstim |
| Ardelyx, INC. | $106.11 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $72.71 | 2023-2025 | Stelara, Tremfya |
| Pfizer INC. | $70.63 | 2022-2023 | |
| Biocon Biologics INC | $47.00 | 2023-2024 | Hulio |
| Merck Sharp & Dohme LLC | $30.07 | 2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $26.06 | 2023 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $24.43 | 2023 | Entyvio |
| Phathom Pharmaceuticals, INC. | $21.58 | 2025 | Voquezna |
| Lilly USA, LLC | $21.36 | 2023 | |
| Novo Nordisk INC | $18.43 | 2025 | Wegovy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $18.17 | 2023 | |
| Celgene Corporation | $16.48 | 2022 | |
| Micro-Tech Endoscopy USA, INC. | $14.82 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.